This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
In the meantime, Takeda and Alnylam have joined the companies working on drug treatments to tackle COVID-19 infections. ... Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
More from news
Approximately 19 fully matching, plus 46 partially matching documents found.
2019 was a landmark year for gene-silencing specialist Alnylam and its chief executive John Maraganore. ... It’s all part of a plan that Maraganore thinks could catapult Alnylam into a top five position in the biopharma category within five years,
Jerini. Commenting on the task ahead at Alnylam, she says: “It’s an incredibly exciting time for the company. ... Alnylam will face a similar process with Europe’s many national HTA organisations.
Two post-referendum announcements have boosted the UK Government. GSK announced a £275 million investment in its UK manufacturing sites and Alnylam, a US biotech worth $6.5bn, said it would
For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of
Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products. ... 300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... He has extensive clinical development experience, a passion for scientific excellence, and
The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...